Atomo Diagnostics Ltd (AT1) - Total Assets
Based on the latest financial reports, Atomo Diagnostics Ltd (AT1) holds total assets worth AU$9.48 Million AUD (≈ $6.71 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Atomo Diagnostics Ltd (AT1) net assets for net asset value and shareholders' equity analysis.
Atomo Diagnostics Ltd - Total Assets Trend (2017–2025)
This chart illustrates how Atomo Diagnostics Ltd's total assets have evolved over time, based on quarterly financial data.
Atomo Diagnostics Ltd - Asset Composition Analysis
Current Asset Composition (June 2025)
Atomo Diagnostics Ltd's total assets of AU$9.48 Million consist of 70.8% current assets and 29.3% non-current assets.
| Asset Category | Amount (AUD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | AU$0.00 | 34.7% |
| Accounts Receivable | AU$617.49K | 6.7% |
| Inventory | AU$1.65 Million | 17.8% |
| Property, Plant & Equipment | AU$1.07 Million | 11.5% |
| Intangible Assets | AU$1.03 Million | 11.1% |
| Goodwill | AU$0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Atomo Diagnostics Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see AT1 market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Atomo Diagnostics Ltd's current assets represent 70.8% of total assets in 2025, a decrease from 88.7% in 2017.
- Cash Position: Cash and equivalents constituted 34.7% of total assets in 2025, down from 69.7% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 11.0% of total assets, an increase from 7.0% in 2017.
- Asset Diversification: The largest asset category is inventory at 17.8% of total assets.
Atomo Diagnostics Ltd Competitors by Total Assets
Key competitors of Atomo Diagnostics Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.54 Billion |
|
Zhejiang Orient Gene Biotech Co Ltd
SHG:688298
|
China | CN¥7.51 Billion |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317
|
China | CN¥3.72 Billion |
|
Guangdong Transtek Medical Electronics Co Ltd
SHE:300562
|
China | CN¥1.42 Billion |
|
Emvision Medical Devices Ltd
AU:EMV
|
Australia | AU$15.57 Million |
|
DRGEM Corporation
KQ:263690
|
Korea | ₩119.28 Billion |
|
Diagnostic Medical Systems SA
PA:ALDMS
|
France | €57.17 Million |
Atomo Diagnostics Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.78 | 3.50 | 16.39 |
| Quick Ratio | 2.14 | 2.44 | 14.98 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | AU$4.47 Million | AU$4.23 Million | AU$28.54 Million |
Atomo Diagnostics Ltd - Advanced Valuation Insights
This section examines the relationship between Atomo Diagnostics Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 4.51 |
| Latest Market Cap to Assets Ratio | 1.48 |
| Asset Growth Rate (YoY) | -18.5% |
| Total Assets | AU$9.28 Million |
| Market Capitalization | $13.76 Million USD |
Valuation Analysis
Above Book Valuation: The market values Atomo Diagnostics Ltd's assets above their book value (1.48x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Atomo Diagnostics Ltd's assets decreased by 18.5% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Atomo Diagnostics Ltd (2017–2025)
The table below shows the annual total assets of Atomo Diagnostics Ltd from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-06-30 | AU$9.28 Million ≈ $6.56 Million |
-18.47% |
| 2024-06-30 | AU$11.38 Million ≈ $8.05 Million |
-30.93% |
| 2023-06-30 | AU$16.47 Million ≈ $11.66 Million |
-38.12% |
| 2022-06-30 | AU$26.62 Million ≈ $18.84 Million |
-17.42% |
| 2021-06-30 | AU$32.24 Million ≈ $22.81 Million |
-10.70% |
| 2020-06-30 | AU$36.10 Million ≈ $25.54 Million |
+496.68% |
| 2019-06-30 | AU$6.05 Million ≈ $4.28 Million |
-21.99% |
| 2018-06-30 | AU$7.76 Million ≈ $5.49 Million |
-34.65% |
| 2017-06-30 | AU$11.87 Million ≈ $8.40 Million |
-- |
About Atomo Diagnostics Ltd
Atomo Diagnostics Limited engages in the development and sale of medical devices worldwide. The company offers blood test devices, such as Pascal, Curie, Galileo, Elion, and Florey under the AtomoRapid brand. It also offers HIV Rapid self-Test device; and digital health solutions. Atomo Diagnostics Limited was incorporated in 2010 and is headquartered in Leichhardt, Australia.